Alector, Inc.

ALEC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $21.0M $100.6M $97.1M $133.6M $207.1M $21.1M $21.2M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $123.1M $185.9M $192.1M $210.4M $189.4M $156.9M $100.5M
SG&A Expense $54.0M $59.6M $56.7M $61.0M $55.0M $59.4M $35.1M
Operating Income $-156.0M $-145.0M $-151.7M $-137.8M $-37.4M $-195.2M $-114.4M
Operating Margin -741.3% -144.2% -156.3% -103.2% -18.0% -925.1% -539.2%
Interest Expense
Pretax Income $-142.8M $-118.9M $-125.1M $-130.1M
Income Tax Expense $168.0K $128.0K $5.2M $3.3M $0 $0 $0
Net Income $-142.9M $-119.0M $-130.4M $-133.3M $-36.3M $-190.2M $-105.4M
Net Margin -679.2% -118.4% -134.3% -99.8% -17.5% -901.6% -496.7%
EPS (Basic) $-1.39 $-1.23 $-1.56 $-1.62 $-0.45 $-2.45 $-1.71
EPS (Diluted) $-1.39 $-1.23 $-1.56 $-1.62 $-0.45 $-2.45 $-1.71
Shares Outstanding (Basic) 110.4M 103.0M 96.6M 83.7M 82.5M 80.4M 77.8M 69.1M
Shares Outstanding (Diluted) 110.4M 103.0M 96.6M 83.7M 82.5M 80.4M 77.8M 69.1M
Dividends Per Share
← Newer Page 1 of 2 Older →